- Home
- Advocacy
- Latest News and Practice Data
- Medicare expands coverage for genetic testing
Our coverage Advocacy program successfully affected two new Medicare local coverage determinations (LCDs) for inherited aortic disease:
- Genetic Testing for Heritable Thoracic Aortic Disease (L39933, MolDx).
- Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935, MolDx).
What's new: Medicare will now cover diagnostic tests used to evaluate and manage care for patients suspected of having Hereditary Transthyretin Amyloidosis (hATTR).
- The LCDs take effect August 17 in 23 states.
How it happened: CAP Advocacy collaborated with the Council on Scientific Affairs and the Biochemical and Molecular Genetics Committee to support coverage for these tests and to ensure that the policies use current evidence.
Go deeper: Read about the CAP’s Medicare coverage advocacy.